search
Back to results

Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function (NEMENDAS)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Estonia
Study Type
Interventional
Intervention
metoprolol succinate
Nebivolol
Sponsored by
Berlin-Chemie AG Menarini Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with mild to moderate essential hypertension (systolic BP 140-179 mmHg and/or diastolic BP 90-109 mmHg)*
  • Male and female patients aged 30-65 years Newly diagnosed untreated patients or previously diagnosed patients who were without treatment at least two weeks prior to screening* If patient has been taken previously antihypertensive medication the BP values are originated after untreated two weeks before randomization

Exclusion Criteria:

  • Concomitant medication: Cyclic antidepressants, MAO inhibitors, corticosteroids
  • Diabetes I or II type (fasting venous plasma glucose > 6.4 mmol/l)
  • Bronchial asthma and chronic obstructive airway disease
  • Body mass index > 30 kg/m2
  • Ischaemic heart disease (III, IV stage, Canadian Cardiovascular Society)
  • Clinically relevant heart failure (NYHA class II - IV)
  • Clinically relevant valve disease (physical examination)
  • Arrhythmias and conduction disturbances, requiring therapy, sinus bradycardia at rest < 50 b/min, sick sinus syndrome, AV - block stage II - III
  • Secondary hypertension (urea >8.3 mmol/l, creatinine >120μmol/l (males), >103 μmol/l (females), TSH > 4.0mIU/l, free T4 > 27 pmol/l)
  • Clinically relevant atherosclerotic disease of lower extremities
  • Acute inflammation (according to CRP > 10mg/l)
  • Hypercholesterolemia (> 6,5 mmol/l)
  • Allergic reaction to beta-blockers
  • Pregnant or breast-feeding women
  • History of hepatic, renal, metabolic or endocrine diseases
  • Smoking > 10 cigarettes per day
  • Alcohol consumption > 7 drinks per week (drink = 0,33 l beer, 120 ml wine or 30 ml strong alcoholic drink)
  • The patient has had surgery or disease of the gastrointestinal tract which, in the opinion of the investigator, may influence the absorption or elimination of the study drug.
  • The patient has a severe organic disorder that may interfere with the absorption, pharmacokinetics, or elimination of the study medication.
  • The patient has a comorbid condition that would be expected to result in death during the trial period (e.g., terminal cancer, AIDS).
  • The patient has chronic psychoses or behavioural conditions that would limit the ability of the patient to comply with the requirements of this study.
  • The patient has known hypersensitivity to Nebivolol, Metoprolol or hydrochlorothiazide related compounds.
  • Patient is enrolled in another clinical trial.

Sites / Locations

  • Cardiology Clinic of Tartu University Clinics

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

metoprolol, tablets

nebivolol

Arm Description

metoprolol succinate 50-100 mg orally daily for one year

nebivolol 5 mg capsule once daily for one year

Outcomes

Primary Outcome Measures

Effects of nebivolol and metoprolol on endothelial function
High-fidelity micromanometer (applanation tonometry) from both wrists and PWA, which is to be performed of the systolic portion (SphygmoCor Px, version 7.0) of the pulse curve.

Secondary Outcome Measures

Change in carotid artery intima-media thickness
Ultrasound scanner,with an 12 MHz transducer. Longitudinal images from 3 projections (anterolateral, lateral, and posterolateral) are measured for the common carotid artery, carotid bulb, and internal carotid artery
Change in left ventricular mass index, systolic and diastolic function
2-dimensional echocardiography using the standard apical 4-chamber view
Arterial Compliance
Peripheral blood pressure and arterial waveform to be measured in the dominant arm by a Cardiovascular Profiling Instrument

Full Information

First Posted
November 19, 2010
Last Updated
November 24, 2010
Sponsor
Berlin-Chemie AG Menarini Group
search

1. Study Identification

Unique Protocol Identification Number
NCT01248338
Brief Title
Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function
Acronym
NEMENDAS
Official Title
Comparison the Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function and Large Artery Stiffness
Study Type
Interventional

2. Study Status

Record Verification Date
November 2010
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Berlin-Chemie AG Menarini Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An impairment of endothelial function plays the central role in the pathogenesis of cardiovascular diseases and their complications. Most of cardiovascular risk factors are known to impair endothelial function and the established disease further aggravates endothelial dysfunction. The aim of the present study is to investigate the effects of nebivolol or metoprolol succinate on endothelial function and large artery stiffness.
Detailed Description
The aim of this study was to compare the effects between the vasodilating β-blocker nebivolol and the cardioselective β-blocker metoprolol succinate on aortic blood pressure and left ventricular wall thickness. We conducted a randomized, double-blind study in 80 hypertensive patients. Patients received either nebivolol 5 mg or metoprolol succinate 50-100 mg daily for one year. Their heart rate, central and brachial blood pressure, mean arterial pressure, augmentation index, carotid-femoral pulse wave velocity and left ventricular wall thickness were measured at baseline and at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
metoprolol, tablets
Arm Type
Active Comparator
Arm Description
metoprolol succinate 50-100 mg orally daily for one year
Arm Title
nebivolol
Arm Type
Experimental
Arm Description
nebivolol 5 mg capsule once daily for one year
Intervention Type
Drug
Intervention Name(s)
metoprolol succinate
Other Intervention Name(s)
Corvitol
Intervention Description
once daily 50 or 100 mg for one year
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Other Intervention Name(s)
Nebilet
Intervention Description
once daily 5 mg capsule for one year
Primary Outcome Measure Information:
Title
Effects of nebivolol and metoprolol on endothelial function
Description
High-fidelity micromanometer (applanation tonometry) from both wrists and PWA, which is to be performed of the systolic portion (SphygmoCor Px, version 7.0) of the pulse curve.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change in carotid artery intima-media thickness
Description
Ultrasound scanner,with an 12 MHz transducer. Longitudinal images from 3 projections (anterolateral, lateral, and posterolateral) are measured for the common carotid artery, carotid bulb, and internal carotid artery
Time Frame
12 months
Title
Change in left ventricular mass index, systolic and diastolic function
Description
2-dimensional echocardiography using the standard apical 4-chamber view
Time Frame
12 months
Title
Arterial Compliance
Description
Peripheral blood pressure and arterial waveform to be measured in the dominant arm by a Cardiovascular Profiling Instrument
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with mild to moderate essential hypertension (systolic BP 140-179 mmHg and/or diastolic BP 90-109 mmHg)* Male and female patients aged 30-65 years Newly diagnosed untreated patients or previously diagnosed patients who were without treatment at least two weeks prior to screening* If patient has been taken previously antihypertensive medication the BP values are originated after untreated two weeks before randomization Exclusion Criteria: Concomitant medication: Cyclic antidepressants, MAO inhibitors, corticosteroids Diabetes I or II type (fasting venous plasma glucose > 6.4 mmol/l) Bronchial asthma and chronic obstructive airway disease Body mass index > 30 kg/m2 Ischaemic heart disease (III, IV stage, Canadian Cardiovascular Society) Clinically relevant heart failure (NYHA class II - IV) Clinically relevant valve disease (physical examination) Arrhythmias and conduction disturbances, requiring therapy, sinus bradycardia at rest < 50 b/min, sick sinus syndrome, AV - block stage II - III Secondary hypertension (urea >8.3 mmol/l, creatinine >120μmol/l (males), >103 μmol/l (females), TSH > 4.0mIU/l, free T4 > 27 pmol/l) Clinically relevant atherosclerotic disease of lower extremities Acute inflammation (according to CRP > 10mg/l) Hypercholesterolemia (> 6,5 mmol/l) Allergic reaction to beta-blockers Pregnant or breast-feeding women History of hepatic, renal, metabolic or endocrine diseases Smoking > 10 cigarettes per day Alcohol consumption > 7 drinks per week (drink = 0,33 l beer, 120 ml wine or 30 ml strong alcoholic drink) The patient has had surgery or disease of the gastrointestinal tract which, in the opinion of the investigator, may influence the absorption or elimination of the study drug. The patient has a severe organic disorder that may interfere with the absorption, pharmacokinetics, or elimination of the study medication. The patient has a comorbid condition that would be expected to result in death during the trial period (e.g., terminal cancer, AIDS). The patient has chronic psychoses or behavioural conditions that would limit the ability of the patient to comply with the requirements of this study. The patient has known hypersensitivity to Nebivolol, Metoprolol or hydrochlorothiazide related compounds. Patient is enrolled in another clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jaan Eha, Professor
Organizational Affiliation
Cardiology Clinic of Tartu University Clinics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cardiology Clinic of Tartu University Clinics
City
Tartu
ZIP/Postal Code
51014
Country
Estonia

12. IPD Sharing Statement

Citations:
PubMed Identifier
22708640
Citation
Serg M, Kampus P, Kals J, Zagura M, Zilmer M, Zilmer K, Kullisaar T, Eha J. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest. 2012 Sep;72(5):427-32. doi: 10.3109/00365513.2012.691991. Epub 2012 Jun 18.
Results Reference
derived
PubMed Identifier
21536983
Citation
Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, Zilmer M, Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011 Jun;57(6):1122-8. doi: 10.1161/HYPERTENSIONAHA.110.155507. Epub 2011 May 2.
Results Reference
derived

Learn more about this trial

Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function

We'll reach out to this number within 24 hrs